RxDoctor Payments Data

Richard Sweeney Jr, MD

Family Medicine · Bartow, FLNPI 1215909254

Payments from drug & device makers

$3,222in general payments, 2019–2025

Across 172 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$994
  • Pfizer$397
  • Biohaven Pharmaceutical Holding Company Ltd.$337
  • Johnson & Johnson$279
  • Novo Nordisk$257
  • Astellas Pharma US Inc$201
  • plus $758 from 15 others

What the payments were for

  • Food & beverage$3,222100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,222 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$336,289
Medicare patients
490
Services billed
6,057

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide272$348,162
EliquisApixaban272$228,009
MounjaroTirzepatide109$141,528
JardianceEmpagliflozin96$104,064
RybelsusSemaglutide61$94,980
XareltoRivaroxaban58$75,372
JanuviaSitagliptin Phosphate73$69,282
FarxigaDapagliflozin Propanediol48$57,649
TrulicityDulaglutide44$52,594
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$37,340
EntrestoSacubitril/Valsartan21$20,267
Tresiba Flextouch U-200Insulin Degludec19$20,095
Repatha SureclickEvolocumab24$19,987
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$19,626
ShingrixVaricella-Zoster Ge/As01b/Pf84$18,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Levemir$257$448,473348 claims
PfizerEliquis$397$228,009272 claims
Lilly USA, LLCMounjaro, Trulicity$34$194,121153 claims
Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Spiriva Respimat$16$132,247138 claims
Johnson & JohnsonXarelto$279$75,37258 claims
GSKTrelegy Ellipta, Shingrix, Anoro Ellipta$156$66,203141 claims
AstraZenecaFarxiga, Symbicort$994$64,66177 claims
Astellas Pharma US IncMyrbetriq$201$11,27216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Bartow

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →